Abstract PR07: A Pediatric Phase 1 Study of Larotrectinib, a Highly Selective Inhibitor of the Tropomyosin Receptor Kinase (TRK) Family: An Updated Analysis
doi 10.1158/1538-7445.pedca17-pr07
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
American Association for Cancer Research